Provided by Tiger Trade Technology Pte. Ltd.

Absci Corporation.

2.76
+0.06502.41%
Post-market: 2.760.00000.00%19:54 EST
Volume:2.65M
Turnover:7.31M
Market Cap:415.03M
PE:-3.08
High:2.83
Open:2.71
Low:2.61
Close:2.70
52wk High:6.33
52wk Low:2.01
Shares:150.37M
Float Shares:127.00M
Volume Ratio:0.65
T/O Rate:2.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8966
EPS(LYR):-0.9353
ROE:-55.68%
ROA:-30.62%
PB:1.97
PE(LYR):-2.95

Loading ...

11 Stocks That Have Cratered and Look Like Buys -- Barrons.com

Dow Jones
·
8 hours ago

Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble

Simply Wall St.
·
Feb 06

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

InvestorPlace
·
Jan 27

Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs

Reuters
·
Jan 15

Absci downgraded to Equal Weight from Overweight at Morgan Stanley

TIPRANKS
·
Jan 08

Absci Price Target Maintained With a $7.00/Share by Needham

Dow Jones
·
Dec 12, 2025

Absci Unveils AI-Designed Antibody That Stimulates Human Hair Growth

Reuters
·
Dec 11, 2025

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

GlobeNewswire
·
Dec 11, 2025

Absci Director Frans Van Houten Reports Acquisition of Common Shares

Reuters
·
Dec 10, 2025

BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial

Reuters
·
Dec 04, 2025

Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss

Reuters
·
Dec 04, 2025

Absci Announces First Participants Dosed in Phase 1/2a Headline™ Trial of AI-Designed Antibody Abs-201™ for Androgenetic Alopecia

THOMSON REUTERS
·
Dec 04, 2025

Absci Corp: Interim Data Anticipated in Second Half of 2026

THOMSON REUTERS
·
Dec 04, 2025

Absci Corp - Phase 2 Development of Abs-201 in Endometriosis Planned for Q4 2026

THOMSON REUTERS
·
Dec 04, 2025

Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade

InvestorPlace
·
Dec 02, 2025

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbSci (ABSI) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Nov 25, 2025

Stock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations

Stock Track
·
Nov 13, 2025

Absci Is Maintained at Buy by Needham

Dow Jones
·
Nov 13, 2025

Stock Track | Absci Corporation Plummets 11.76% in Pre-market Following Disappointing Q3 Results

Stock Track
·
Nov 13, 2025

Stock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss

Stock Track
·
Nov 13, 2025